Drugs / Amb a 1 Immunostimulatory Conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00346086 | May → Aug 2001 | seasonal allergic rhinitis | Johns Hopkins University | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amb a 1 Immunostimulatory Conjugate | “AIC (Amb a 1 Immunostimulatory Conjugate)” NCT00346086 ↗ |
| Known as | AIC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00346086 ↗ |
| Action | Activate | “Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.” PMID 17021320 ↗ Oct 2006 |
| Modality | Vaccine | “a vaccine consisting of Amb a 1, a ragweed-pollen antigen, conjugated to a phosphorothioate oligodeoxyribonucleotide immunostimulatory sequence of DNA (AIC)” PMID 17021320 ↗ Oct 2006 |
| Route | Subcutaneous | “Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC)” NCT00346086 ↗ |
| Target | TLR9 | “Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.” PMID 17021320 ↗ Oct 2006 |